View ValuationBio-Rad Laboratories 将来の成長Future 基準チェック /16Bio-Rad Laboratories利益と収益がそれぞれ年間3.6%と1.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に2.9% 3.6%なると予測されています。主要情報3.6%収益成長率3.63%EPS成長率Life Sciences 収益成長20.2%収益成長率1.7%将来の株主資本利益率2.93%アナリストカバレッジLow最終更新日30 Jul 2026今後の成長に関する最新情報お知らせ • Aug 05Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023Bio-Rad Laboratories, Inc. is updating its financial outlook for full-year 2023. The company currently expects non-GAAP currency-neutral revenue growth of approximately 0.8% in 2023 compared to its previous estimate of 4.5 % and an estimated non-GAAP operating margin of about 16.0% versus the company's prior estimate of approximately 17.5%. Excluding COVID-related sales, Bio-Rad estimates full-year 2023 non-GAAP currency-neutral revenue growth to be about 4.5% compared to its prior expectation of approximately 8.5%.すべての更新を表示Recent updatesお知らせ • Jul 24Bio-Rad Laboratories, Inc. to Report Q2, 2026 Results on Aug 04, 2026Bio-Rad Laboratories, Inc. announced that they will report Q2, 2026 results on Aug 04, 2026お知らせ • Apr 17Bio-Rad Laboratories, Inc. to Report Q1, 2026 Results on Apr 30, 2026Bio-Rad Laboratories, Inc. announced that they will report Q1, 2026 results After-Market on Apr 30, 2026お知らせ • Mar 27Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 21, 2026Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 21, 2026. Location: 1000 alfred nobel drive, california 94547, hercules United Statesお知らせ • Feb 13Bio-Rad Laboratories, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025Bio-Rad Laboratories, Inc. reported impairment charges for the fourth quarter ended December 31, 2025. For the quarter, the company reported impairment of purchased intangibles and related items of $172.8 million.お知らせ • Jan 29Bio-Rad Laboratories, Inc. to Report Q4, 2025 Results on Feb 12, 2026Bio-Rad Laboratories, Inc. announced that they will report Q4, 2025 results After-Market on Feb 12, 2026お知らせ • Oct 17Bio-Rad Laboratories, Inc. to Report Q3, 2025 Results on Oct 29, 2025Bio-Rad Laboratories, Inc. announced that they will report Q3, 2025 results After-Market on Oct 29, 2025お知らせ • Sep 30Bio-Rad Laboratories, Inc. Announces Demise of Alice N. Schwartzas, Co-Founder and DirectorBio-Rad Laboratories, Inc. announced that Alice N. Schwartz, Bio-Rad’s co-founder and Director Emeritus, passed away on September 25, 2025, at the age of 99. Mrs. Schwartz co-founded Bio-Rad in 1952 in Berkeley, California, together with her husband David Schwartz, shortly after graduating with a biochemistry degree from the University of California, Berkeley. Mrs. Schwartz played a key role in Bio-Rad’s achievements and remained an active Board member until 2022. Her leadership and passion for scientific discovery created a legacy that continues to inspire the company and the broader scientific community.お知らせ • Jul 29Bio-Rad Laboratories, Inc. Appoints Rajat Mehta as Executive Vice President, Global Commercial Operations, Effective August 4, 2025Bio-Rad Laboratories, Inc. announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company’s West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India.お知らせ • Jul 18Bio-Rad Laboratories, Inc. to Report Q2, 2025 Results on Jul 31, 2025Bio-Rad Laboratories, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025お知らせ • Jul 07Bio-Rad Laboratories, Inc. Announces Launch of Four New Droplet Digital™? PCR (ddPCR™?) PlatformsBio-Rad Laboratories, Inc. announced the launch of four new Droplet Digital™? PCR (ddPCR™?) platforms. The newly introduced instruments include Bio-Rad's QX Continuum™? ddPCR system along with the QX700™? series of ddPCR platforms acquired as part of the company's recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad's existing line of QX200™? and QX600™? ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows. The QX Continuum™?dPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate. The QX700™? series consistsof three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.お知らせ • Jul 02An unknown affiliate of Bio-Rad Laboratories, Inc. (NYSE:BIO) completed the acquisition of Stilla Technologies SA.An unknown affiliate of Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a binding offer to acquire Stilla Technologies SA for approximately $280 million on February 13, 2025. On March 18, 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a share purchase agreement to acquire Stilla Technologies SA. Bio-Rad Laboratories will pay approximately $225 million in cash, as well as potential future contingent milestone payments for a maximum amount of up to $50 million. The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025. Anne-Charlotte Rivière, Benhouda Derradji, Marie Fillion and Charles-Henri de Gouvion Saint Cyr of Goodwin Procter (France) LLP, Sarah Jordan, Gretchen Scott and Martin Gomez of Goodwin Procter (Uk) Llp and Martin Gomez and Daniel S Karelitz of Goodwin Procter LLP acted as legal advisor to Stilla Technologies SA and the sellers. Freshfields Bruckhaus Deringer LLP acted as legal advisor to Bio-Rad Laboratories. TD Securities Inc. acted as financial advisor to Stilla Technologies SA. An unknown affiliate of Bio-Rad Laboratories, Inc. (NYSE:BIO) completed the acquisition of Stilla Technologies SA on June 30, 2025.お知らせ • Apr 23Biodesix, Inc. and Bio-Rad Laboratories, Inc. Submits New Research Findings from Friends of Cancer Research's ctMoniTR ProjectBiodesix, Inc. and Bio-Rad Laboratories contributed to new research findings from Friends of Cancer Research's ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care. The ctMoniTR Project (ctDNA to Monitor Treatment Response) was designed to determine whether changes in levels of ctDNA predict treatment outcomes for patients. Results from the first phase of the project demonstrated a strong link between changes in ctDNA and overall survival in patients with aNSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data, from the second phase of ctMoniTR, expands the analysis to additional solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors. Led by Friends, collaborators included Biodesix alongside organizations from industry, government, academia, and advocacy groups. Biodesix contributed data generated using Bio-Rad Droplet Digital™? PCR (ddPCR™?) technology to detect ctDNA from patient samples. Beyond this specific research project, Biodesix offers ctDNA testing, using ddPCR technology, as part of its Development Services portfolio and is also exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD). The latest advancements in this application will be presented at the American Association for Cancer Research (AACR) Annual Meeting, April 28th, 2025.お知らせ • Apr 16Bio-Rad Laboratories, Inc. to Report Q1, 2025 Results on May 01, 2025Bio-Rad Laboratories, Inc. announced that they will report Q1, 2025 results After-Market on May 01, 2025お知らせ • Mar 27Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 22, 2025Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 22, 2025. Location: 1000 alfred nobel drive, california 94547, hercules, United Statesお知らせ • Feb 14Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a binding offer to acquire Stilla Technologies SA.Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a binding offer to acquire Stilla Technologies SA on February 13, 2025. The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.お知らせ • Jan 28Bio-Rad Laboratories, Inc. to Report Q4, 2024 Results on Feb 13, 2025Bio-Rad Laboratories, Inc. announced that they will report Q4, 2024 results After-Market on Feb 13, 2025お知らせ • Oct 15Bio-Rad Laboratories, Inc. to Report Q3, 2024 Results on Oct 30, 2024Bio-Rad Laboratories, Inc. announced that they will report Q3, 2024 results After-Market on Oct 30, 2024お知らせ • Sep 23+ 1 more updateBio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)お知らせ • Aug 20Bio-Rad Laboratories, Inc. Announces Executive ChangesBio-Rad Laboratories, Inc. announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company’s several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health Division at PerkinElmer, a global company focused on diagnostics, life science research, food quality, environmental health and industrial testing. He also served as Chief Executive Officer of Enzymatics, a privately held molecular biology reagents company. Prior to that, Mr. DiVincenzo held roles of increasing responsibility in the Biosciences and Lab Water businesses of EMD Millipore, a subsidiary of Merck KGaA. He holds a Bachelor of Science degree in mechanical engineering from Northeastern University.お知らせ • Jul 18Bio-Rad Laboratories, Inc. to Report Q2, 2024 Results on Aug 01, 2024Bio-Rad Laboratories, Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024お知らせ • May 31Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024Bio-Rad Laboratories, Inc. announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a leading global molecular diagnostics company. While at Cepheid, Ms. Engelhardt was Senior Vice President and General Manager overseeing the emerging growth opportunities business, as well as Senior Vice President of global research and development, strategy, product management and marketing functions supporting the company’s extensive product portfolio. Prior to Cepheid, Ms. Engelhardt held several senior positions at bioMerieux Inc., a global leader in vitro diagnostics, including Senior Vice President of the company’s new technologies franchise and microbiology business unit. In these roles, she was responsible for developing and implementing product and market strategies for bioMerieux’s range of microbiology-related reagents, instruments, and services, as well as leveraging and commercializing new technologies. Ms. Engelhardt’s career also includes tenure as CEO of privately held AB BIODISK, where she managed the in vitro diagnostics company’s post-acquisition integration into bioMerieux. She began her career as a process engineer at AB BIODISK and holds a combined Master of Science and Bachelor of Science degree in Chemical Engineering and Polymer Technology from the Royal Institute of Technology in Stockholm, Sweden.お知らせ • Apr 27Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science GroupOn April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024. On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024. Mr. Barry succeeds Dr. May in this position. For the past two years, James Barry has been responsible for Bio-Rad’s global manufacturing operations including quality, planning, and continuous improvement initiatives across the organization. Prior to his role within Global Manufacturing, he oversaw Bio-Rad’s Quality Systems Division, which provides third-party independent quality control materials and data management software for hospitals and reference labs globally. Mr. Barry joined Bio-Rad in 2017 from Beckman Coulter where he led sales of the lab automation and genomics portfolio to academic, pharmaceutical, and government customers. He holds a B.S. degree in Mechanical Engineering from Rose Hulman Institute of Technology and an MBA from Pepperdine University.お知らせ • Apr 20Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024Bio-Rad Laboratories, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Apr 11Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to RetireBio-Rad Laboratories, Inc. announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.お知らせ • Mar 28Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024, at 16:00 Pacific Daylight. Location: 1000 Alfred Nobel Drive, Hercules, California 94547 California United States Agenda: To approve the election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock; to ratify the selection of KPMG LLP as company independent auditors for the fiscal year ending December 31, 2024; to approve the amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan; and to approve Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.お知らせ • Mar 20+ 1 more updateBio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024Bio-Rad Laboratories, Inc. announced that Roop K. Lakkaraju will join the company as its new Executive Vice President effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company’s global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Support.com, a provider of cloud-based software and services, and Solectron, a leading global provider of electronics manufacturing and integrated supply chain services. Mr. Lakkaraju began his career as an auditor with Grant Thornton and PricewaterhouseCoopers, and holds a B.S. in Business Administration, Accounting, from San Jose State University.お知らせ • Feb 16Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial OfficerOn February 9, 2024, Bio-Rad Laboratories, Inc.’s board of directors appointed Norman Schwartz, the Company’s President and Chief Executive Officer and the Chairman of the Board, as the Company’s principal financial officer until a permanent replacement for Ilan Daskal has been appointed.お知らせ • Jan 25Bio-Rad Laboratories, Inc. to Report Q4, 2023 Results on Feb 15, 2024Bio-Rad Laboratories, Inc. announced that they will report Q4, 2023 results After-Market on Feb 15, 2024お知らせ • Dec 08Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024On December 4, 2023, Dara Grantham Wright, the Executive Vice-President and President, Clinical Diagnostics Group, of Bio-Rad Laboratories, Inc. and a named executive officer of the Company, notified the Company of her plans to resign from the Company to pursue another opportunity, effective at the close of business on January 12, 2024. The Company has initiated a search to fill this position.お知らせ • Oct 18+ 1 more updateBio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Executive Vice-President and Principal Financial Officer, Effective November 6, 2023On October 12, 2023, Ilan Daskal, the Executive Vice-President of Bio-Rad Laboratories, Inc. (the “Company”) and the Company’s principal financial officer, notified the Company of his plans to resign from the Company to pursue another opportunity, effective at the close of business on November 6, 2023. The Company has initiated a search to fill this position.お知らせ • Oct 06Bio-Rad Laboratories, Inc. to Report Q3, 2023 Results on Oct 26, 2023Bio-Rad Laboratories, Inc. announced that they will report Q3, 2023 results After-Market on Oct 26, 2023お知らせ • Aug 26Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective September 18, 2023Bio-Rad Laboratories, Inc. announced on August 21, 2023, Ajit Ramalingam, the Senior Vice-President, Chief Accounting Officer of the company and the company’s principal accounting officer, notified the company of his plans to resign from the company, effective at the close of business on September 18, 2023. The company has initiated a search to fill this position. Upon effectiveness of Mr. Ramalingam’s resignation and until a permanent successor is appointed by the company, Tania DeVilliers will act as the company’s interim principal accounting officer, in addition to her current position as Senior Director, Corporate Controller. Ms. DeVilliers has been a certified public accountant since 2008 and a Chartered Accountant since 1996, and she has over twenty-five years of experience in accounting and financial management roles. Ms. DeVilliers, age 50, joined the Company as Senior Director, Corporate Controller in June 2021. She worked at PricewaterhouseCoopers, a leading global professional services organization specializing in advisory, tax and assurance services, from December 1998 until she joined the Company in June 2021, in positions of increasing responsibility, most recently holding the title of Audit Director starting in 2015.お知らせ • Aug 05Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023Bio-Rad Laboratories, Inc. is updating its financial outlook for full-year 2023. The company currently expects non-GAAP currency-neutral revenue growth of approximately 0.8% in 2023 compared to its previous estimate of 4.5 % and an estimated non-GAAP operating margin of about 16.0% versus the company's prior estimate of approximately 17.5%. Excluding COVID-related sales, Bio-Rad estimates full-year 2023 non-GAAP currency-neutral revenue growth to be about 4.5% compared to its prior expectation of approximately 8.5%.お知らせ • Jul 12Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023Bio-Rad Laboratories, Inc. announced that they will report Q2, 2023 results After-Market on Aug 03, 2023お知らせ • Jan 07Bio-Rad Laboratories, Inc. to Report Q4, 2022 Results on Feb 16, 2023Bio-Rad Laboratories, Inc. announced that they will report Q4, 2022 results After-Market on Feb 16, 2023業績と収益の成長予測DB:BUW - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,676228326467312/31/20272,635230314445512/31/20262,56722531245953/31/20262,590169357510N/A12/31/20252,583760375532N/A9/30/20252,558-676337492N/A6/30/20252,554319348534N/A3/31/20252,541-2,164332515N/A12/31/20242,567-1,844266455N/A9/30/20242,580-779224412N/A6/30/20242,563-1,326177346N/A3/31/20242,605-322185347N/A12/31/20232,671-637218375N/A9/30/20232,720-159223374N/A6/30/20232,769-428153287N/A3/31/20232,779-191125242N/A12/31/20222,802-3,62780194N/A9/30/20222,805-6,021152286N/A6/30/20222,871-1,930364505N/A3/31/20222,896-91459606N/A12/31/20212,9234,254536670N/A9/30/20212,9806,659670783N/A6/30/20212,8804,045590689N/A3/31/20212,7014,098533626N/A12/31/20202,5463,814480585N/A9/30/20202,3803,521378450N/A6/30/20202,2941,947323414N/A3/31/20202,3291,579383478N/A12/31/20192,3121,759N/A458N/A9/30/20192,304377N/A403N/A6/30/20192,289905N/A366N/A3/31/20192,292574N/A288N/A12/31/20182,289366N/A285N/A9/30/20182,2941,277N/A250N/A6/30/20182,2831,030N/A216N/A3/31/20182,212767N/A201N/A12/31/20172,160122N/A104N/A9/30/20172,11017N/A130N/A6/30/20172,08513N/A153N/A3/31/20172,09726N/A168N/A12/31/20162,06826N/A216N/A9/30/20162,06798N/A157N/A6/30/20162,02897N/A188N/A3/31/20162,018108N/A149N/A12/31/20152,019109N/A186N/A9/30/20152,047103N/A190N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BUWの予測収益成長率 (年間3.6% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: BUWの収益 ( 3.6% ) German市場 ( 15.4% ) よりも低い成長が予測されています。高成長収益: BUWの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: BUWの収益 ( 1.7% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: BUWの収益 ( 1.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BUWの 自己資本利益率 は、3年後には低くなると予測されています ( 2.9 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 02:22終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio-Rad Laboratories, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Jon WoodBofA Global ResearchYuan ZhiB. Riley Securities, Inc.Patrick DonnellyCitigroup Inc17 その他のアナリストを表示
お知らせ • Aug 05Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023Bio-Rad Laboratories, Inc. is updating its financial outlook for full-year 2023. The company currently expects non-GAAP currency-neutral revenue growth of approximately 0.8% in 2023 compared to its previous estimate of 4.5 % and an estimated non-GAAP operating margin of about 16.0% versus the company's prior estimate of approximately 17.5%. Excluding COVID-related sales, Bio-Rad estimates full-year 2023 non-GAAP currency-neutral revenue growth to be about 4.5% compared to its prior expectation of approximately 8.5%.
お知らせ • Jul 24Bio-Rad Laboratories, Inc. to Report Q2, 2026 Results on Aug 04, 2026Bio-Rad Laboratories, Inc. announced that they will report Q2, 2026 results on Aug 04, 2026
お知らせ • Apr 17Bio-Rad Laboratories, Inc. to Report Q1, 2026 Results on Apr 30, 2026Bio-Rad Laboratories, Inc. announced that they will report Q1, 2026 results After-Market on Apr 30, 2026
お知らせ • Mar 27Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 21, 2026Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 21, 2026. Location: 1000 alfred nobel drive, california 94547, hercules United States
お知らせ • Feb 13Bio-Rad Laboratories, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025Bio-Rad Laboratories, Inc. reported impairment charges for the fourth quarter ended December 31, 2025. For the quarter, the company reported impairment of purchased intangibles and related items of $172.8 million.
お知らせ • Jan 29Bio-Rad Laboratories, Inc. to Report Q4, 2025 Results on Feb 12, 2026Bio-Rad Laboratories, Inc. announced that they will report Q4, 2025 results After-Market on Feb 12, 2026
お知らせ • Oct 17Bio-Rad Laboratories, Inc. to Report Q3, 2025 Results on Oct 29, 2025Bio-Rad Laboratories, Inc. announced that they will report Q3, 2025 results After-Market on Oct 29, 2025
お知らせ • Sep 30Bio-Rad Laboratories, Inc. Announces Demise of Alice N. Schwartzas, Co-Founder and DirectorBio-Rad Laboratories, Inc. announced that Alice N. Schwartz, Bio-Rad’s co-founder and Director Emeritus, passed away on September 25, 2025, at the age of 99. Mrs. Schwartz co-founded Bio-Rad in 1952 in Berkeley, California, together with her husband David Schwartz, shortly after graduating with a biochemistry degree from the University of California, Berkeley. Mrs. Schwartz played a key role in Bio-Rad’s achievements and remained an active Board member until 2022. Her leadership and passion for scientific discovery created a legacy that continues to inspire the company and the broader scientific community.
お知らせ • Jul 29Bio-Rad Laboratories, Inc. Appoints Rajat Mehta as Executive Vice President, Global Commercial Operations, Effective August 4, 2025Bio-Rad Laboratories, Inc. announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company’s West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India.
お知らせ • Jul 18Bio-Rad Laboratories, Inc. to Report Q2, 2025 Results on Jul 31, 2025Bio-Rad Laboratories, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025
お知らせ • Jul 07Bio-Rad Laboratories, Inc. Announces Launch of Four New Droplet Digital™? PCR (ddPCR™?) PlatformsBio-Rad Laboratories, Inc. announced the launch of four new Droplet Digital™? PCR (ddPCR™?) platforms. The newly introduced instruments include Bio-Rad's QX Continuum™? ddPCR system along with the QX700™? series of ddPCR platforms acquired as part of the company's recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad's existing line of QX200™? and QX600™? ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows. The QX Continuum™?dPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate. The QX700™? series consistsof three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.
お知らせ • Jul 02An unknown affiliate of Bio-Rad Laboratories, Inc. (NYSE:BIO) completed the acquisition of Stilla Technologies SA.An unknown affiliate of Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a binding offer to acquire Stilla Technologies SA for approximately $280 million on February 13, 2025. On March 18, 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a share purchase agreement to acquire Stilla Technologies SA. Bio-Rad Laboratories will pay approximately $225 million in cash, as well as potential future contingent milestone payments for a maximum amount of up to $50 million. The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025. Anne-Charlotte Rivière, Benhouda Derradji, Marie Fillion and Charles-Henri de Gouvion Saint Cyr of Goodwin Procter (France) LLP, Sarah Jordan, Gretchen Scott and Martin Gomez of Goodwin Procter (Uk) Llp and Martin Gomez and Daniel S Karelitz of Goodwin Procter LLP acted as legal advisor to Stilla Technologies SA and the sellers. Freshfields Bruckhaus Deringer LLP acted as legal advisor to Bio-Rad Laboratories. TD Securities Inc. acted as financial advisor to Stilla Technologies SA. An unknown affiliate of Bio-Rad Laboratories, Inc. (NYSE:BIO) completed the acquisition of Stilla Technologies SA on June 30, 2025.
お知らせ • Apr 23Biodesix, Inc. and Bio-Rad Laboratories, Inc. Submits New Research Findings from Friends of Cancer Research's ctMoniTR ProjectBiodesix, Inc. and Bio-Rad Laboratories contributed to new research findings from Friends of Cancer Research's ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care. The ctMoniTR Project (ctDNA to Monitor Treatment Response) was designed to determine whether changes in levels of ctDNA predict treatment outcomes for patients. Results from the first phase of the project demonstrated a strong link between changes in ctDNA and overall survival in patients with aNSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data, from the second phase of ctMoniTR, expands the analysis to additional solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors. Led by Friends, collaborators included Biodesix alongside organizations from industry, government, academia, and advocacy groups. Biodesix contributed data generated using Bio-Rad Droplet Digital™? PCR (ddPCR™?) technology to detect ctDNA from patient samples. Beyond this specific research project, Biodesix offers ctDNA testing, using ddPCR technology, as part of its Development Services portfolio and is also exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD). The latest advancements in this application will be presented at the American Association for Cancer Research (AACR) Annual Meeting, April 28th, 2025.
お知らせ • Apr 16Bio-Rad Laboratories, Inc. to Report Q1, 2025 Results on May 01, 2025Bio-Rad Laboratories, Inc. announced that they will report Q1, 2025 results After-Market on May 01, 2025
お知らせ • Mar 27Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 22, 2025Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 22, 2025. Location: 1000 alfred nobel drive, california 94547, hercules, United States
お知らせ • Feb 14Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a binding offer to acquire Stilla Technologies SA.Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a binding offer to acquire Stilla Technologies SA on February 13, 2025. The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.
お知らせ • Jan 28Bio-Rad Laboratories, Inc. to Report Q4, 2024 Results on Feb 13, 2025Bio-Rad Laboratories, Inc. announced that they will report Q4, 2024 results After-Market on Feb 13, 2025
お知らせ • Oct 15Bio-Rad Laboratories, Inc. to Report Q3, 2024 Results on Oct 30, 2024Bio-Rad Laboratories, Inc. announced that they will report Q3, 2024 results After-Market on Oct 30, 2024
お知らせ • Sep 23+ 1 more updateBio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)
お知らせ • Aug 20Bio-Rad Laboratories, Inc. Announces Executive ChangesBio-Rad Laboratories, Inc. announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company’s several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health Division at PerkinElmer, a global company focused on diagnostics, life science research, food quality, environmental health and industrial testing. He also served as Chief Executive Officer of Enzymatics, a privately held molecular biology reagents company. Prior to that, Mr. DiVincenzo held roles of increasing responsibility in the Biosciences and Lab Water businesses of EMD Millipore, a subsidiary of Merck KGaA. He holds a Bachelor of Science degree in mechanical engineering from Northeastern University.
お知らせ • Jul 18Bio-Rad Laboratories, Inc. to Report Q2, 2024 Results on Aug 01, 2024Bio-Rad Laboratories, Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024
お知らせ • May 31Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024Bio-Rad Laboratories, Inc. announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a leading global molecular diagnostics company. While at Cepheid, Ms. Engelhardt was Senior Vice President and General Manager overseeing the emerging growth opportunities business, as well as Senior Vice President of global research and development, strategy, product management and marketing functions supporting the company’s extensive product portfolio. Prior to Cepheid, Ms. Engelhardt held several senior positions at bioMerieux Inc., a global leader in vitro diagnostics, including Senior Vice President of the company’s new technologies franchise and microbiology business unit. In these roles, she was responsible for developing and implementing product and market strategies for bioMerieux’s range of microbiology-related reagents, instruments, and services, as well as leveraging and commercializing new technologies. Ms. Engelhardt’s career also includes tenure as CEO of privately held AB BIODISK, where she managed the in vitro diagnostics company’s post-acquisition integration into bioMerieux. She began her career as a process engineer at AB BIODISK and holds a combined Master of Science and Bachelor of Science degree in Chemical Engineering and Polymer Technology from the Royal Institute of Technology in Stockholm, Sweden.
お知らせ • Apr 27Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science GroupOn April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024. On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024. Mr. Barry succeeds Dr. May in this position. For the past two years, James Barry has been responsible for Bio-Rad’s global manufacturing operations including quality, planning, and continuous improvement initiatives across the organization. Prior to his role within Global Manufacturing, he oversaw Bio-Rad’s Quality Systems Division, which provides third-party independent quality control materials and data management software for hospitals and reference labs globally. Mr. Barry joined Bio-Rad in 2017 from Beckman Coulter where he led sales of the lab automation and genomics portfolio to academic, pharmaceutical, and government customers. He holds a B.S. degree in Mechanical Engineering from Rose Hulman Institute of Technology and an MBA from Pepperdine University.
お知らせ • Apr 20Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024Bio-Rad Laboratories, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Apr 11Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to RetireBio-Rad Laboratories, Inc. announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.
お知らせ • Mar 28Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024, at 16:00 Pacific Daylight. Location: 1000 Alfred Nobel Drive, Hercules, California 94547 California United States Agenda: To approve the election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock; to ratify the selection of KPMG LLP as company independent auditors for the fiscal year ending December 31, 2024; to approve the amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan; and to approve Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
お知らせ • Mar 20+ 1 more updateBio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024Bio-Rad Laboratories, Inc. announced that Roop K. Lakkaraju will join the company as its new Executive Vice President effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company’s global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Support.com, a provider of cloud-based software and services, and Solectron, a leading global provider of electronics manufacturing and integrated supply chain services. Mr. Lakkaraju began his career as an auditor with Grant Thornton and PricewaterhouseCoopers, and holds a B.S. in Business Administration, Accounting, from San Jose State University.
お知らせ • Feb 16Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial OfficerOn February 9, 2024, Bio-Rad Laboratories, Inc.’s board of directors appointed Norman Schwartz, the Company’s President and Chief Executive Officer and the Chairman of the Board, as the Company’s principal financial officer until a permanent replacement for Ilan Daskal has been appointed.
お知らせ • Jan 25Bio-Rad Laboratories, Inc. to Report Q4, 2023 Results on Feb 15, 2024Bio-Rad Laboratories, Inc. announced that they will report Q4, 2023 results After-Market on Feb 15, 2024
お知らせ • Dec 08Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024On December 4, 2023, Dara Grantham Wright, the Executive Vice-President and President, Clinical Diagnostics Group, of Bio-Rad Laboratories, Inc. and a named executive officer of the Company, notified the Company of her plans to resign from the Company to pursue another opportunity, effective at the close of business on January 12, 2024. The Company has initiated a search to fill this position.
お知らせ • Oct 18+ 1 more updateBio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Executive Vice-President and Principal Financial Officer, Effective November 6, 2023On October 12, 2023, Ilan Daskal, the Executive Vice-President of Bio-Rad Laboratories, Inc. (the “Company”) and the Company’s principal financial officer, notified the Company of his plans to resign from the Company to pursue another opportunity, effective at the close of business on November 6, 2023. The Company has initiated a search to fill this position.
お知らせ • Oct 06Bio-Rad Laboratories, Inc. to Report Q3, 2023 Results on Oct 26, 2023Bio-Rad Laboratories, Inc. announced that they will report Q3, 2023 results After-Market on Oct 26, 2023
お知らせ • Aug 26Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective September 18, 2023Bio-Rad Laboratories, Inc. announced on August 21, 2023, Ajit Ramalingam, the Senior Vice-President, Chief Accounting Officer of the company and the company’s principal accounting officer, notified the company of his plans to resign from the company, effective at the close of business on September 18, 2023. The company has initiated a search to fill this position. Upon effectiveness of Mr. Ramalingam’s resignation and until a permanent successor is appointed by the company, Tania DeVilliers will act as the company’s interim principal accounting officer, in addition to her current position as Senior Director, Corporate Controller. Ms. DeVilliers has been a certified public accountant since 2008 and a Chartered Accountant since 1996, and she has over twenty-five years of experience in accounting and financial management roles. Ms. DeVilliers, age 50, joined the Company as Senior Director, Corporate Controller in June 2021. She worked at PricewaterhouseCoopers, a leading global professional services organization specializing in advisory, tax and assurance services, from December 1998 until she joined the Company in June 2021, in positions of increasing responsibility, most recently holding the title of Audit Director starting in 2015.
お知らせ • Aug 05Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023Bio-Rad Laboratories, Inc. is updating its financial outlook for full-year 2023. The company currently expects non-GAAP currency-neutral revenue growth of approximately 0.8% in 2023 compared to its previous estimate of 4.5 % and an estimated non-GAAP operating margin of about 16.0% versus the company's prior estimate of approximately 17.5%. Excluding COVID-related sales, Bio-Rad estimates full-year 2023 non-GAAP currency-neutral revenue growth to be about 4.5% compared to its prior expectation of approximately 8.5%.
お知らせ • Jul 12Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023Bio-Rad Laboratories, Inc. announced that they will report Q2, 2023 results After-Market on Aug 03, 2023
お知らせ • Jan 07Bio-Rad Laboratories, Inc. to Report Q4, 2022 Results on Feb 16, 2023Bio-Rad Laboratories, Inc. announced that they will report Q4, 2022 results After-Market on Feb 16, 2023